經歷

英國伯明罕大學（University of Birmingham）心血管科學系教授 (2024-present)、心血管科學系英國心臟基金會（BHF）教授 (2004-2024)、心血管科學中心主任/副主任 (2012-2015)、心血管科學系副系主任 (2015-2020)、醫學院研究生研究主管 (2013-2017)、醫學院授課型碩士學位主管 (2014-2016)

英國牛津大學（University of Oxford）藥理學系英國心臟基金會（BHF）高級研究員 (1998-2004)、皇家學會大學研究員 (1988-1998)、藥理學系示範員 (1985-1988)、聖艾德蒙學堂（St Edmund Hall）醫學導師 (1996–1998, 2001-2003)及特別選舉院士 (1990–2004)

美國北卡羅萊納州巴勒斯·威康公司（Burroughs Wellcome）博士後研究員 (1983–1985)

榮譽與獎項

重要學術機構院士與研究員殊榮：

英國醫學科學院院士 Fellow of Academy of Medical Sciences (2002-)

英國藥理學會院士 Fellow of the British Pharmacology Society (2012-)

英國心臟基金會高級研究員 British Heart Foundation Senior Research Fellow (1998)

皇家學會大學研究員 Royal Society University Research Fellow (1988)

多項國際學術殊榮與科學獎項：

血小板學會 Gus Born 獎 Platelet Society Gus Born Award (2025)

創新醫藥技術優秀獎 Pharmaceutical Technology Excellent Award in Innovation (2023)

靜脈學會勳章：澳大利亞靜脈學院血栓與止血基礎科學研究卓越獎 Order of Phlebology Medal (2013)

國際血栓與止血學會（ISTH）止血貢獻研究者認可獎 ISTH Investigator Recognition Award (2007)

Nature/NESTA 科學創意導師中期獎 Nature/NESTA Mid-Career Award for Creative Mentoring in Science (2006)

荷蘭馬斯特里赫特大學 Coen Hemker 客座教授 (2017)、中國徐州醫科大學客座教授 (2018)

高品質學術期刊的主編與編輯職務： 

國際血小板領域權威期刊《Platelets》聯合總編輯 Editor-in-Chief (2015–2022) 及編輯 (2005–2014)

《Arteriosclerosis Thrombosis and Vascular Biology》編輯 (2012–2014)

《Biochemical Journal》編輯 (2010–2012)

《Thrombosis and Haemostasis》編輯 (2008–2012)

《Journal of Biological Chemistry》編輯 (2008–2013)

《Journal of Thrombosis and Haemostasis》編輯 (2007–2013)

《Trends in Pharmacological Sciences (TiPS)》編輯 (2001-)

《Current Opinion in Pharmacology》編輯 (2001–2009)

研究方向及研究室特色

Watson 教授長期獲得英國心臟基金會（BHF）、威康信託基金會（Wellcome Trust）及生物技術與生物科學研究委員會（BBSRC）等權威機構的巨額經費支持（包含主持多項超過百萬英鎊的重大研究計畫與加速器計畫）。其實驗室主要專注於血小板活化途徑、巨核細胞分化、血栓形成以及血管完整性的尖端生物醫學研究。他的團隊在闡明血小板膠原蛋白受體 GPVI 以及 C 型凝集素樣受體 CLEC-2 的訊號傳導機制（如 hemITAM 傳導途徑）方面做出了里程碑式的貢獻。近年來，其實驗室更跨足奈米抗體（Nanobody）技術，成功研發出能針對 GPVI 受體進行選擇性抑制的新型抗血栓配體，並已正式提出「Nanobody」國際專利申請（PCT/EP2021/087129）。Watson 教授在學術界享有崇高聲望，發表超過 380 篇高水平論文，其 H-index 高達 115，更成功指導了超過 67 位博士生（DPhil/PhD）及數十位博士後研究員成為生技醫藥界與學術界的中流砥柱。

專利

精選論文(共發表386篇研究論文及多篇評論、專書)

1 Lamerton RE, Martin EM, Perry J, Cunningham AF, Watson SP, Frelinger ALF. (2025) A minimal valency of four is required for robust activation of platelets by multivalent nanobodies to GPVI, CLEC-2 and PEAR1. Research and Practice in Thrombosis and Haemostasis 9:e103196.
2 Martin EM, Clark JC, Montague SJ, Morán LA, Di Y, Bull LJ, Whittle L, Raka F, Buka RJ, Zafar I, Kardeby C, Slater A, Watson SP. (2024) Trivalent nanobody-based ligands mediate powerful activation of GPVI, CLEC-2 and PEAR1 in human platelets whereas FcγRIIA requires a tetravalent ligand. Journal of Thrombosis and Haemostasis 22:271–285.
3 Xu R-G, Tiede C, Calabrese AN, Cheah LT, Adams TL, Gauer JS, Hindle MS, Slater A, Duval C, Naseem KM, Herr AB, Tomlinson DC, Watson SP, Ariëns RAS. (2024) Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer. Blood Advances 8:3917–3928.
4 Gauer JS, Duval C, Xu R-G, Macrae FL, Tiede C, Tomlinson D, Watson SP, Ariëns RAS. (2023) Fibrin-GPVI interaction increases platelet procoagulant activity and impacts clot structure. Journal of Thrombosis and Haemostasis 21:667–681.
5 Jooss NJ, Smith CW, Slater A, Di Y, O’Shea C, Thomas MR, Henskens Y, Heemskerk JWM, Watson SP, Poulter NS. (2022) Anti-GPVI nanobody blocks collagen- and atherosclerotic plaque-induced GPVI clustering, signaling and thrombus formation. Journal of Thrombosis and Haemostasis 20:2617–2631.
6 Smith C, Montague S, Kardeby C, Di Y, Lowe G, Lester W, Watson SP, Nicolson PLR. (2021) Anti-platelet drugs block platelet activation by vaccine-induced immune thrombocytopenia and thrombosis patient serum. Blood 138:2733–2740.
7 Poulter NS, Pollitt AY, Owen DM, Gardiner EE, Andrews RK, Shimizu H, Ishikawa D, Bihan D, Farndale RW, Moroi M, Watson SP, Jung SM. (2017) Clustering of GPVI dimers upon adhesion to collagen as a mechanism to regulate GPVI signalling in platelets. Journal of Thrombosis and Haemostasis 15:549–564.
8 Payne H, Ponomaryov T, Watson SP, Brill A. (2017) Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood 129:2013–2020.
9 Hughes CE, Finney BA, Lowe KL, Koentgen F, Watson SP. (2015) The N-terminal SH2 domain of Syk is required for (hem)ITAM but not integrin signalling in mouse platelets. Blood 125:144–154.
10 Navarro-Núñez L, Pollitt AY, Lowe K, Latif A, Nash GB, Watson SP. (2015) Platelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilized by Src/Syk-dependent platelet signaling. Thrombosis and Haemostasis 113:1109–1112.
11 Pollitt AY, Poulter N, Gitz E, Navarro-Núñez L, Wang Y-J, Hughes CE, Thomas SG, Nieswandt B, Douglas MR, Owen DM, Jackson DG, Dustin ML, Watson SP. (2014) Syk and Src family kinases regulate CLEC-2 mediated clustering of Podoplanin and platelet adhesion to lymphatic endothelial cells. Journal of Biological Chemistry 289:35695–35710.
12 Watson SP, Herbert JMJ, Pollitt AY. (2010) Glycoprotein VI and CLEC-2 in hemostasis and vascular integrity. Journal of Thrombosis and Haemostasis 8:1456–1467.
13 Christou CM, Pearce AC, Watson AA, Mistry AR, Pollitt AY, Fenton-May AE, Johnson LA, Jackson DG, Watson SP, O’Callaghan C. (2008) Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochemical Journal 411:133–140.
14 Auger JM, Watson SP. (2008) Dynamic tyrosine kinase-regulated signalling and actin polymerisation mediate aggregate stability under shear. Arteriosclerosis, Thrombosis, and Vascular Biology 28:1499–1504.
15 Fuller GLF, Williams JAE, Tomlinson MG, Eble MG, Hanna SL, Pöhlmann S, Suzuki-Inoue K, Ozaki Y, Watson SP, Pearce AC. (2007) The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signalling cascade. Journal of Biological Chemistry 282:12397–12409.
16 Calaminus SDJ, Auger JM, McCarty OJT, Wakelam MJO, Machesky LM, Watson SP. (2007) MyosinIIa contractility is required for maintenance of platelet structure during spreading on collagen and contributes to thrombus stability. Journal of Thrombosis and Haemostasis 5:2136–2145.
17 Suzuki-Inoue K, Fuller GLJ, Garcia A, Eble JA, Pöhlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, Theakston RDG, Schweighoffer E, Zitzmann N, Morita T, Tybulewicz VLJ, Ozaki Y, Watson SP. (2006) A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 107:542–549.
18 Auger JM, Kuijpers MJ, Senis YA, Watson SP, Heemskerk JW. (2005) Adhesion of human and mouse platelets to collagen under shear: a unifying model. FASEB Journal 19:825–827.
19 McCarty OJT, Larson MK, Auger JM, Kalia N, Atkinson BT, Pearce AC, Ruf S, Henderson RB, Tybulewicz VLJ, Machesky LM, Watson SP. (2005) Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. Journal of Biological Chemistry 280:39474–39484.
20 Watson SP, Auger JM, McCarty O, Pearce A. (2005) GPVI and integrin signalling in platelets and their biological significance under flow. Journal of Thrombosis and Haemostasis 3:1752–1763.
21 Suzuki-Inoue K, Wilde JI, Andrews RK, Auger JA, Siraganian RP, Sekiya F, Rhee SG, Watson SP. (2004) GPVI and GPIb/IX/V stimulate tyrosine phosphorylation of Syk and PLCγ2 at distinct sites. Biochemical Journal 378:1023–1029.
22 Nieswandt B, Watson SP. (2003) GPVI: the central collagen receptor. Blood 102:449–461.
23 Pasquet J-M, Gross B, Quek L, Asazuma N, Zhang W, Sommers CL, Schweighoffer E, Tybulewicz V, Judd B, Lee JR, Koretzky G, Love PE, Samelson LE, Watson SP. (1999) LAT is required for tyrosine phosphorylation of phospholipase Cγ2 and platelet activation by the collagen receptor GPVI. Molecular and Cellular Biology 19:8326–8334.
24 Quek L, Bolen J, Watson SP. (1998) A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Current Biology 8:1137–1140.
25 Gibbins JM, Okuma M, Farndale R, Barnes M, Watson SP. (1997) Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor γ-chain. FEBS Letters 413:255–259.